Piramal Pharma Limited

rs,

5th November, 2025 BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 National Stock Exchange of India Limi

11%

nue from Operations CDMO CHG ICH EBITDA EBITDA Margin PAT 2,044 1,044 644 319 224 11% (99) 2,242 1,324 643 277 403 18% 23 (9)% (21)% 0% 15% (44)% NM 3,977 2,041

18%

BITDA EBITDA Margin PAT 2,044 1,044 644 319 224 11% (99) 2,242 1,324 643 277 403 18% 23 (9)% (21)% 0% 15% (44)% NM 3,977 2,041 1,281 621 389 10% (181) 4,193 2,38

0%

T 2,044 1,044 644 319 224 11% (99) 2,242 1,324 643 277 403 18% 23 (9)% (21)% 0% 15% (44)% NM 3,977 2,041 1,281 621 389 10% (181) 4,193 2,381 1,274 541 627 15%

15%

2,044 1,044 644 319 224 11% (99) 2,242 1,324 643 277 403 18% 23 (9)% (21)% 0% 15% (44)% NM 3,977 2,041 1,281 621 389 10% (181) 4,193 2,381 1,274 541 627 15% (66

10%

1,324 643 277 403 18% 23 (9)% (21)% 0% 15% (44)% NM 3,977 2,041 1,281 621 389 10% (181) 4,193 2,381 1,274 541 627 15% (66) YoY Growth (5)% (14)% 1% 15% (38)% N

1%

281 621 389 10% (181) 4,193 2,381 1,274 541 627 15% (66) YoY Growth (5)% (14)% 1% 15% (38)% NM Key Highlights for Q2 and H1 FY26 • Revenue from Operations for the quarter an

₹ 2,044 crore

ghlights for Q2 and H1 FY26 • Revenue from Operations for the quarter and half-year FY26 stood at ₹ 2,044 crores and ₹ 3,977 crores respectively. The YoY growth was impacted due to inventory destocking by the c

₹ 3,977 crore

H1 FY26 • Revenue from Operations for the quarter and half-year FY26 stood at ₹ 2,044 crores and ₹ 3,977 crores respectively. The YoY growth was impacted due to inventory destocking by the customer in one larg

₹ 228 crore

towards cost optimization and operational excellence. • Net-Debt at the end of H1FY26 reduced by ₹ 228 crores (vs. FY25) to ₹ 3,971 crores supported by tight control over working capital and capex investmen

₹ 3,971 crore

nd operational excellence. • Net-Debt at the end of H1FY26 reduced by ₹ 228 crores (vs. FY25) to ₹ 3,971 crores supported by tight control over working capital and capex investments, maintaining our net debt

3x

control over working capital and capex investments, maintaining our net debt to EBITDA ratio below 3x. • Sustainability– Released our 4th Annual Sustainability Report for the FY25, under the theme ‘In

“❖ Expect better revenue and EBITDA performance going forward driven by: • Significant uptick in biopharma funding in months of September and October 2025.”

“643 644 H1FY25 H1FY26 Q2FY25 Q2FY26 9 COLOR PALETTE Piramal Consumer Healthcare Business Performance Highlights Revenue Growth ❖ 15% Revenue growth in Q2 and H1 FY26 – faster than market growth.”

“15% 621 ❖ E-commerce sales grew at over 40% YoY in Q2 and H1 FY26, contributing ~24% to PCH sales.”

“Products launched in last 24 months contributed 8% to PCH sales in FY25.”

For Investor Queries

2

The dial-in details for the call are as under

1

About Piramal Pharma Limited

1

For Media Queries

1

The dial-in details for the call are as under

Event Location & Time Telephone Number India – 09:30 AM IST +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) 1 800 120 1221 (Toll free number) Toll free number 18667462133 Toll free number 08081011573 Toll free number 8001012045 Toll free number 800964448 USA – 11:00 AM (Eastern Time – New York) UK – 04:00 AM (London Time) Singapore – 12:00 PM (Singapore Time) Hong Kong – 12:00 PM (Hong Kong Time) Please use this link for prior registration to reduce wait time at the time of joining the call –Click here Conference call on 06th November, 2025 Express Join with Diamond Pass™

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn 1. Includes one facility via PPL’s minorit

For Media Queries

Madiha Vahid Lead – Branding & Communications madiha.vahid@piramal.com Madhusudan Dalmia Investor Relations madhusudan.dalmia@piramal.com COLOR PALETTE Q2FY26 Results November 2025 COLOR PALETTE Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue

For Investor Queries

Gagan Borana Investor Relations and Enterprise Risk Management Email: gagan.borana@piramal.com Madhusudan Dalmia Investor Relations Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited www.piramalpharma.com Complex Hospital Generics www.piramalcriticalcare.com CDMO www.piramalpharmasolutions.com Piramal Consumer Healthcare www.wellify.in